In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Manchester Innovation Ltd.

Executive Summary

Manchester Innovation Ltd.'s role goes beyond commercializing intellectual property generated by the university and managing the biotechnology incubator building on the university's behalf. Where some other universities' technology transfer initiatives stop at helping with the formation and financing of spin-out companies, MIL aims to provide its spin-outs with ongoing help to develop into successful enterprises.

You may also be interested in...



Renovo Ltd.

There are currently no effective pharmacological treatments to prevent scarring following trauma or surgery. Renovo, a spin-off from the University of Manchester, was set up two years ago with this market in mind. Renovo has two anti-scarring compounds in clinical trials, based on Transforming Growth Factor Beta 3, which appears to promote healing without scarring in embryos, and an antagonist of Transforming Growth Factor Beta 1 and Beta 2, growth factors which appear to be associated with scarring in adults.

Senexis Ltd.

Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.

Private Device Companies Step-Up to the Public Market

Encouraged by successes in the biotech space, public market investors' interest in the device arena has returned in 2004 to support 10 companies' IPOs so far. Windhover's analysis of the valuations achieved indicate that private investors in these companies have, on average, enjoyed larger returns than their biotech counterparts.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel